User:Mr. Ibrahem/Metamizole

From Wikipedia, the free encyclopedia
Not to be confused with methimazole or methazolamide.
Mr. Ibrahem/Metamizole
Clinical data
Trade namesNovalgin, others[1][2]
Other namesDipyrone (BAN UK, USAN US)
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  • Not assigned; no evidence of teratogenicity in animals, use in 3rd trimester may cause heart problems[3]
Routes of
administration		By mouth, IM, IV, rectal
Legal status
Legal status
  • Over-the-counter (some countries); prescription-only (others); withdrawn (others)
Pharmacokinetic data
Bioavailability100% (active metabolites)[4]
Protein binding48–58% (active metabolites)[4]
MetabolismLiver[4]
Elimination half-life14 minutes (parent compound; parenteral);[3] metabolites: 2–4 hours[4]
ExcretionUrine (96%, IV; 85%, oral), faeces (4%, IV).[3]
Identifiers
  • [(2,3-Dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylamino] methanesulfonic acid
Chemical and physical data
FormulaC13H17N3O4S
Molar mass311.36 g·mol−1
3D model (JSmol)
  • c1ccccc1N2N(C)C(C)=C(C2=O)N(C)CS(=O)(=O)O
  • InChI=1S/C13H17N3O4S/c1-10-12(14(2)9-21(18,19)20)13(17)16(15(10)3)11-7-5-4-6-8-11/h4-8H,9H2,1-3H3,(H,18,19,20) ☒N
  • Key:LVWZTYCIRDMTEY-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Metamizole, also known as dipyrone, is a pain medication, spasm reliever, and fever reducer.[5] It may be used when other medications are not effective.[5] Onset is rapid and effects last up to 8 hours.[6] It is may be given by mouth, rectally, or by injection.[5]

Common side effects include sleepiness, abdominal discomfort, and nausea.[7] Serious side effects my include allergic reactions, including anaphylaxis, and low white blood cells.[8] While it appears relatively safe in early pregnancy, there are concerns in later pregnancy.[5] Use is not recommended when breastfeeding.[5] It is in the ampyrone family of medicines.[9] It is not an opioid; though sources differ regarding if it is an NSAID.[10][6]

Metamizole was patented in 1922 and was first used medically in Germany.[11][12] It is marketed under various trade names.[2] It was withdrawal from market in a number of countries, including the United States and United Kingdom, in the 1960s and 70s due to side effects.[13][7] Though it remains available in parts of Europe and the developing world as of 2019.[5][7]

References[edit]

  1. ^ Brune, K (1997). "The early history of non-opioid analgesics". Acute Pain. 1: 33–40. doi:10.1016/S1366-0071(97)80033-2.
  2. ^ a b "Metamizole". Drugs.com. Archived from the original on 23 October 2017. Retrieved 16 July 2021.
  3. ^ a b c "Fachinformation (Zusammenfassung der Merkmale des Arzneimittels) Novaminsulfon injekt 1000 mg Lichtenstein Novaminsulfon injekt 2500 mg Lichtenstein" (PDF). Winthrop Arzneimittel GmbH (in German). Zinteva Pharm GmbH. February 2013. Archived (PDF) from the original on 16 October 2018. Retrieved 19 April 2014.
  4. ^ a b c d Jage J, Laufenberg-Feldmann R, Heid F (April 2008). "[Drugs for postoperative analgesia: routine and new aspects. Part 1: non-opioids]" [Drugs for postoperative analgesia: routine and new aspects. Part 1: non-opioids]. Der Anaesthesist (in German). 57 (4): 382–90. doi:10.1007/s00101-008-1326-x. PMID 18351305. S2CID 32814418.
  5. ^ a b c d e f "Metamizole containing medicinal products". https://www.ema.europa.eu. Archived from the original on 4 March 2021. Retrieved 16 July 2021. {{cite web}}: External link in |website= (help)
  6. ^ a b Nikolova, Irina; Tencheva, Jasmina; Voinikov, Julian; Petkova, Valentina; Benbasat, Niko; Danchev, Nikolai (January 2012). "Metamizole: A Review Profile of a Well-Known "Forgotten" Drug. Part I: Pharmaceutical and Nonclinical Profile". Biotechnology & Biotechnological Equipment. 26 (6): 3329–3337. doi:10.5504/BBEQ.2012.0089.
  7. ^ a b c Aronson, Jeffrey K. (22 December 2009). Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs. Elsevier. p. 198. ISBN 978-0-08-093294-1. Archived from the original on 28 August 2021. Retrieved 16 July 2021.
  8. ^ Lutz, Mathias (November 2019). "Metamizole (Dipyrone) and the Liver: A Review of the Literature". The Journal of Clinical Pharmacology. 59 (11): 1433–1442. doi:10.1002/jcph.1512. PMID 31433499.
  9. ^ Prabhakar, Hemanshu; Ali, Zulfiqar (15 April 2019). Textbook of Neuroanesthesia and Neurocritical Care: Volume I - Neuroanesthesia. Springer. p. 442. ISBN 978-981-13-3387-3. Archived from the original on 29 August 2021. Retrieved 16 July 2021.
  10. ^ Jasiecka, A; Maślanka, T; Jaroszewski, JJ (2014). "Pharmacological characteristics of metamizole". Polish journal of veterinary sciences. 17 (1): 207–14. doi:10.2478/pjvs-2014-0030. PMID 24724493.
  11. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 530. ISBN 9783527607495. Archived from the original on 2021-08-29. Retrieved 2020-09-04.
  12. ^ Silverman, Milton; Lydecker, Mia; Lee, Philip (1 May 1992). Bad Medicine: The Prescription Drug Industry in the Third World. Stanford University Press. p. 90. ISBN 978-0-8047-6667-8. Archived from the original on 29 August 2021. Retrieved 16 July 2021.
  13. ^ United Nations Department of Economic and Social Affairs (2005). Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted of Not Approved by Governments (PDF) (12th ed.). New York: United Nations. pp. 171–5. Archived (PDF) from the original on 21 April 2021. Retrieved 3 April 2013.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Metamizole&oldid=1134529519"